QuantalX

Focus: QuantalX is a biotechnology company developing DELPhI, a non-invasive probe technology for direct visualization of brain networks, with initial applications in neurological and psychiatric disorders. The company operates as a pre-revenue biotech from Israel focused on diagnostic medical device validation.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About QuantalX

AI assessmentNot Hiring

No open roles listed right now. Follow QuantalX to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Delphi-MD device

Traumatic Brain Injury

N/A

Clinical Trials (1)

NCT06963775Assessment of Traumatic Brain Injury Using Transcranial Magnetic Stimulated Evoked Potentials

N/A

Help build intelligence for QuantalX

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering medical device technology in high-unmet-need neurodiagnostics with potential to transform brain disorder assessment
Early-stage opportunity to shape clinical development and regulatory strategy across multiple neurological indications (stroke, TBI, depression)
Focused pipeline with 6 active clinical/retrospective studies validating core DELPhI platform across diverse neurologic conditions

Watch Out For

No active hiring (0 open positions) and undisclosed funding/employee count signal financial constraints or early-stage scaling challenges
All programs in retrospective or early validation phases (no formal Phase 1-3 trials listed), indicating preclinical/translational stage rather than clinical momentum
No disclosed revenue, publications, or recent news; extreme data opacity limits visibility into scientific credibility, commercial viability, or organizational health

Generated by Claude from QuantalX's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

This is a retrospective analysis study of data collected with a diagnostic medical device

Neurologic Disorder

N/A

Clinical Trials (1)

NCT06368024Establishment of Delphi-MD Safety Performance and Reliability

N/A

No intervention, this is a retrospective study.

Healthy

N/A

Clinical Trials (1)

NCT04095377Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.

N/A

DELPhI Evaluation of Psychiatric Conditions

Major Depressive Disorder

N/A

Clinical Trials (1)

NCT03842345DELPhI Evaluation of Psychiatric Conditions

N/A

DELPhI

Stroke

N/A

Clinical Trials (1)

NCT03832413Characterization of the DELPhI System in Assessing Brain's Functionality in Different Neurological Disorders